← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Kinoxis Therapeutics Pty Ltd
Camberwell
$6,402,913
Total funding
2
Grants
Funding over time
peak $2.8M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,402,913 · 2
By mechanism
UH3$3,603,973 · 1
UG3$2,798,940 · 1
Investigators at Kinoxis Therapeutics Pty Ltd
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program.$2,798,940
UG3 · FY2019 · DA
Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program.$2,149,117
UH3 · FY2023 · DA
Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program.$1,004,351
UH3 · FY2024 · DA
Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program.$450,505
UH3 · FY2025 · DA